| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Rhodiosin targets cytochrome P450 2D6 (CYP2D6) as a specific non-competitive inhibitor with an IC50 of 27.77 μM, and also exhibits potent DPPH free radical scavenging activity, contributing to its antioxidant, anti-inflammatory, and neuroprotective properties.
|
|---|---|
| ln Vitro |
By altering the feedback of the HIF-1α signal, rodiosin (10 μM, 24 h) modifies the protective effect on the central nervous system [3].
In vitro studies demonstrate that Rhodiosin exhibits potent DPPH radical scavenging activity with an IC50 of 27.77 μM, indicating strong antioxidant capacity; it also shows specific non-competitive inhibition of CYP2D6, a key drug-metabolizing enzyme. |
| ln Vivo |
Rhodiola rosea (100 mg/kg, injury, once daily, for 10 consecutive days) can lessen radiation-induced neck damage and the amount of MDA in the irradiated C57BL mice model [4].
In vivo, Rhodiosin has been reported to act as an adaptogen, enhancing resilience against stress and fatigue, with antioxidant and neuroprotective effects observed in animal models, though detailed in vivo studies are more limited compared to in vitro findings. |
| Enzyme Assay |
The in vitro enzyme assay for CYP2D6 inhibition involves incubating Rhodiosin with recombinant CYP2D6 enzyme and a fluorogenic substrate (e.g., 3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin), measuring the production of fluorescent metabolite over time, with IC50 values calculated from inhibition curves and mode of inhibition determined by Lineweaver-Burk analysis.
|
| Cell Assay |
Western Blot Analysis [3]
Cell Types: BV-2 and PC-12 Tested Concentrations: 10 μM Incubation Duration: 24 h Experimental Results: HIF-1α degradation in BV-2 and PC-12 cells was diminished under normoxic conditions, and under hypoxic conditions HIF-1α protein expression was enhanced in PC-12 cells. In vitro cell culture studies utilize neuronal cell lines or primary neurons treated with Rhodiosin, assessing neuroprotective effects against oxidative stress induced by hydrogen peroxide or glutamate, measuring cell viability by MTT, reactive oxygen species by DCFH-DA fluorescence, and inflammatory mediators by ELISA or qPCR. |
| Animal Protocol |
Animal/Disease Models: Irradiated C57BL mouse model [4]
Doses: 100 mg/kg, one time/day for 10 days. Route of Administration: po (oral gavage). Experimental Results: Radiation caused a decrease in MDA content in the liver. In vivo animal experiments involve administering Rhodiosin to rodent models of stress, fatigue, or neurodegeneration via oral gavage or intraperitoneal injection, assessing behavioral outcomes (e.g., forced swim test, open field test), measuring oxidative stress markers in brain tissues, and evaluating neuroprotective effects through histopathological analysis. |
| ADME/Pharmacokinetics |
Rhodiosin is a glycosylated flavonoid with molecular weight 610.52 g/mol; it is typically provided as a primary reference standard with ≥85% purity (HPLC), stored at room temperature or 2-8°C, and is soluble in DMSO and methanol.
|
| Toxicity/Toxicokinetics |
Toxicological data for Rhodiosin are limited; as a natural product from Rhodiola species, it is generally considered safe at moderate doses, with adaptogenic effects reported, though comprehensive toxicity profiles in animals are not extensively documented for the pure compound.
|
| References |
|
| Additional Infomation |
Reports indicate that Rhodiola crenulata, Rhodiola sachalinensis, and Rhodiola rosea contain rhodioloside, and relevant data is available for reference.
Rhodiosin is a research compound and reference standard used for studying the pharmacological activities of Rhodiola species, including antioxidant, anti-inflammatory, and neuroprotective mechanisms; it has not been approved for clinical use and serves as a tool for investigating CYP2D6 inhibition and flavonoid bioactivity. |
| Molecular Formula |
C27H30O16
|
|---|---|
| Molecular Weight |
610.5175
|
| Exact Mass |
610.153
|
| CAS # |
86831-54-1
|
| PubChem CID |
76959646
|
| Appearance |
Light yellow to green yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
994.3±65.0 °C at 760 mmHg
|
| Flash Point |
329.1±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.765
|
| LogP |
-2.25
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
43
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(C3=C(C(=C2)O)C(=O)C(=C(O3)C4=CC=C(C=C4)O)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O
|
| InChi Key |
WXBBQBYCUTXTJQ-ULMXTSOFSA-N
|
| InChi Code |
InChI=1S/C27H30O16/c1-8-15(31)25(43-26-21(37)19(35)16(32)13(7-28)41-26)22(38)27(39-8)40-12-6-11(30)14-18(34)20(36)23(42-24(14)17(12)33)9-2-4-10(29)5-3-9/h2-6,8,13,15-16,19,21-22,25-33,35-38H,7H2,1H3/t8-,13+,15-,16+,19-,21+,22+,25+,26-,27-/m0/s1
|
| Chemical Name |
7-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-6-methyl-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5,8-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~54.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6379 mL | 8.1897 mL | 16.3795 mL | |
| 5 mM | 0.3276 mL | 1.6379 mL | 3.2759 mL | |
| 10 mM | 0.1638 mL | 0.8190 mL | 1.6379 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
